ACE2 Modulators for Coronavirus Cytokine Storm Mitigation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for COVID-19, particularly SARS-CoV-19, fail to effectively manage acute inflammatory responses and cytokine storms, leading to severe respiratory issues and mortality.
Innovation Solution
Administering angiotensin converting enzyme-2 (ACE2) modulators, such as inhibitors, to reduce inflammation and prevent cytokine storms by targeting the ACE2 receptor, which is crucial for viral entry into host cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ACE2 modulators are administered to reduce inflammation and prevent cytokine storms, then patient survival rates improve and mortality reduces, but the complexity of treatment protocols increases
Solution Approach 1:
The patent uses ACE2 modulators as intermediary substances that mediate between the virus-ACE2 interaction and the inflammatory response. By targeting the ACE2 receptor, these modulators prevent viral entry while also regulating the inflammatory pathway, thus improving survival rates without requiring complex multi-drug regimens
Solution Approach 2:
The patent changes the biochemical parameters of the ACE2 enzyme through modulator administration. By altering the activity state of ACE2 (inhibiting or modulating its function), the treatment transforms the pathological inflammatory response into a controlled state, improving patient outcomes while maintaining relatively simple administration protocols
2Object-affected harmful factors
If ACE2 modulators are used to treat coronavirus symptoms, then acute inflammatory responses are reduced and cytokine storms are prevented, but the understanding of ACE2's dual role becomes more complex
Solution Approach 1:
The patent converts the harmful effect of ACE2 (as a viral entry receptor) into a beneficial therapeutic target. By administering ACE2 modulators, the treatment exploits the ACE2-inflammasome interaction pathway to suppress harmful cytokine storms while maintaining or enhancing ACE2's protective metabolic functions, thus transforming a vulnerability into a therapeutic opportunity
3Reliability
If ACE2 modulators are administered to reduce viral load and prevent ARDS, then disease progression is halted, but the timing and dosing requirements become more critical
Solution Approach 1:
The patent emphasizes preliminary administration of ACE2 modulators before the development of severe inflammatory responses and cytokine storms. By initiating treatment early in the disease course, the modulators prevent the activation of the inflammasome pathway and block viral entry, halting disease progression before ARDS develops and reducing the criticality of precise timing windows
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of ACE2 modulators effectively alleviates symptoms like fever, cough, and ARDS, reduces viral load, and prevents progression to life-threatening complications by mitigating the hyper-inflammatory response.
Implementation Method 1
The coronaviruses SARS-CoV and SARS-COV-19 mediate their host cell entry via attachment to ACE2-membrane receptors. SARS-CoV-19 enters the lungs, where the spike glycoprotein of the virus binds to ACE2 on cells, allowing the virus to enter the cells.
Implementation Method 2
The present disclosure is based on the discovery that ACE2 is a therapeutic target for the treatment of coronavirus symptoms, in particular in reducing inflammation and preventing cytokine storms in patients with coronavirus infections, in particular SARS-CoV-19.
Data Source
AI summary
The present disclosure relates to methods of treating at least one symptom of a coronavirus infection, or preventing an acute inflammatory response, e.g., a cytokine storm in a coronavirus patient, in particular a SARS-CoV-19 patient, by administering an angiontensin converting enzyme-2 (ACE2) modulator.